Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deferred Tax Liability (2018 - 2020)

Akebia Therapeutics has reported Non-Current Deferred Tax Liability over the past 3 years, most recently at $35.1 million for Q1 2020.

  • Quarterly Non-Current Deferred Tax Liability rose 806.04% to $35.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $35.1 million through Mar 2020, up 806.04% year-over-year, with the annual reading at $119.4 million for FY2018, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability was $35.1 million for Q1 2020 at Akebia Therapeutics, up from $1.8 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $119.4 million in Q4 2018 and troughed at $1.8 million in Q3 2019.
  • The 3-year median for Non-Current Deferred Tax Liability is $3.9 million (2019), against an average of $32.6 million.
  • The largest YoY upside for Non-Current Deferred Tax Liability was 806.04% in 2020 against a maximum downside of 806.04% in 2020.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $119.4 million in 2018, then crashed by 98.53% to $1.8 million in 2019, then soared by 1903.42% to $35.1 million in 2020.
  • Per Business Quant, the three most recent readings for AKBA's Non-Current Deferred Tax Liability are $35.1 million (Q1 2020), $1.8 million (Q3 2019), and $3.0 million (Q2 2019).